People: Cadus Corp (KDUS.OB)

KDUS.OB on OTC BB

1.36USD
21 May 2013
Price Change (% chg)

$-0.01 (-0.73%)
Prev Close
$1.37
Open
$1.36
Day's High
$1.36
Day's Low
$1.36
Volume
371
Avg. Vol
6,743
52-wk High
$1.44
52-wk Low
$1.33

Search Stocks

Summary

Name Age Since Current Position

David Blitz

 79 2004 Acting President, Chief Executive Officer, Treasurer, Secretary

James Broach

 64 1998 Independent Director

Brett Icahn

 33 2010 Independent Director

Peter Liebert

 76 1995 Independent Director

Jack Wasserman

 76 1996 Independent Director
» Insider Trading

Biographies

Name Description

David Blitz

 Mr. David Blitz is Acting President, Chief Executive Officer, Treasurer and Secretary of Cadus Corporation in May 2004. Mr. Blitz, a retired partner of Deloitte & Touche, has been employed as a certified public accountant by Joel Popkin & Co., P.C. since January 1990. Mr. Blitz, as an employee of Joel Popkin & Co., P.C., has been performing Cadus Corporation's internal accounting since March 2000. He earned his B.A. in Economics from Brooklyn College.

James Broach

 Dr. James R. Broach, Ph.D., serves as Independent Director of Cadus Corporation since 1998. He is a scientific founder of Cadus and inventor of Cadus’s yeast–based drug discovery technology, has been Director of Research of Cadus since its inception. He is currently Chair of the Department of Biochemistry and Molecular Biology at Penn State University College of Medicine and Director of the Penn State Hershey Institute for Personalized Medicine. From 1984 to 2012, he was Professor of Molecular Biology at Princeton University, where he served as Associate Chair and Associate Director of the Lewis Sigler Institute for Integrative Genomics. In 1984, Dr. Broach and his collaborators were the first ones to demonstrate that human genes could be implanted into yeast cells. Dr. Broach is a member of the Scientific Advisory Board of the U.S. Food and Drug Administration and until 2012 was member of the Board of Trustees of the University of Medicine and Dentistry of New Jersey and a Commissioner on the New Jersey Commission for Cancer Research. He received his Ph.D. in Biochemistry from University of California at Berkeley and his B.S. from Yale University. The Board of Directors has concluded that Dr. Broach should serve as a director of Cadus because of his role as the inventor of Cadus's yeast-based discovery technology and his continuing association and prominence in academic circles in the field of Molecular Biology.

Brett Icahn

 Mr. Brett C. Icahn is Independent Director of Cadus Corp., since July 2010. Since April 2010, he is responsible for co-executing a small/mid-cap investment strategy across all industries as a Portfolio Manager of the Sargon Portfolio for Icahn Capital LP, the entity through which Carl C. Icahn manages investment funds. From 2002 through April 2010, Brett Icahn was an investment analyst at Icahn Capital. He has served as a director of The Hain Celestial Group, Inc. (a natural and organic products company) since July 2010, as a director of Take-Two Interactive Software, Inc. (a developer, marketer and publisher of software games) since April 2010, as a director of Motricity, Inc. (a mobile data solutions provider) and as a member of its Nominating and Corporate Governance Committees since January 2010, and as a director and member of the Compensation Committee of American Railcar Industries, Inc. (a company that is primarily engaged in the business of manufacturing covered hopper and tank railcars) since January 2007. Prior to that Mr. Icahn served on the board of directors of HowStuffWorks.com, an internet website acquired by Discovery Communications in 2007. He received a B.A. from Princeton University.

Peter Liebert

 Dr. Peter S. Liebert, M.D., is an Independent Director of Cadus Corp., since April 1995. Dr. Liebert has been a pediatric surgeon in private practice since 1968 and is Chief of Pediatric Surgery at the Stamford Hospital in Stamford, Connecticut. He is a past president of the Westchester Surgical Society. He is also a past president of the Westchester County Medical Society and is currently Chairman of its Finance Committee. He is also Chairman of the Board of Rx Vitamins, Inc. Dr. Liebert served as a director of ImClone Systems Incorporated from October 2006 to November 2008. Dr. Liebert holds an M.D. from Harvard University Medical School and a B.A. from Princeton University.

Jack Wasserman

 Mr. Jack G. Wasserman serves as an Independent Director of Cadus Corp., since May 1996. Mr. Wasserman is an attorney and a member of the Bars of New York, Florida, and the District of Columbia. From 1966 until 2001 he was a senior partner of Wasserman, Schneider, Babb & Reed, a New York-based law firm and its predecessors. Since September 2001 Mr. Wasserman has been engaged in the practice of law as a sole practitioner. Since 1993 he has been a director of Icahn Enterprises G.P., Inc. (formerly American Property Investors, Inc.), the general partner of Icahn Enterprises L.P. (formerly American Real Estate Partners, L.P.). Mr. Carl C. Icahn controls Icahn Enterprises G.P. and its subsidiaries. Mr. Wasserman has been licensed by the New Jersey State Casino Control Commission and the Nevada State Gaming Control Commission. Since December 1, 1998, Mr. Wasserman has been a director of National Energy Group, Inc. On March 11, 2004, Mr. Wasserman was appointed to the Board of Directors of Triarc Companies, Inc. and was elected to the Board in June 2004; in 2008 Triarc acquired Wendy’s Inc., and Triarc changed its name to Wendy’s/Arby’s Group Inc.; he serves as a member of Wendy’s/Arby’s Board of Directors’ audit and compensation committees and is chairman of the Board’s ERISA committee. Mr. Wasserman received a B.A. from Adelphi University, a J.D. from Georgetown University Law Center, and a Graduate Diploma from Johns Hopkins University School of Advanced International Studies. In 2007 he received a professional Certificate in Financial Analysis from New York University’s School of Continuing and Professional Studies in Bologna, Italy.

Basic Compensation

Name Fiscal Year Total

David Blitz

 25,000

James Broach

 --

Brett Icahn

 --

Peter Liebert

 --

Jack Wasserman

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

David Blitz

 0 0

James Broach

 0 0

Brett Icahn

 0 0

Peter Liebert

 0 0

Jack Wasserman

 0 0

Insider Trading

Name Shares Traded Price

MOAB CAPITAL PARTNERS L L C

 250,000 $1.43
» Full list on Insider Trading
Search Stocks